Shizhifang ameliorates pyroptosis of renal tubular epithelial cells in hyperuricemia through inhibiting NLRP3 inflammasome
Bibliographic Data
| ID | 14729659 |
|---|---|
| Authors | Jiabao Zhou (0009-0004-8547-9491, Shuguang Hospital), Chuanxu Wang (0000-0001-6253-4196, Shuguang Hospital), Xuming Zhang (0000-0002-9326-5547, Shanghai University of Traditional Chinese Medicine), Zhiyuan Wu (0000-0002-0142-5639, Shanghai University of Traditional Chinese Medicine), Yansheng Wu (Shuguang Hospital), Dongdong Li (0000-0001-9000-7158), Dong‐Dong Li (0000-0002-8085-9557, Shuguang Hospital), Jiandong Gao (0000-0002-1645-837X, Shuguang Hospital, corresponding author) |
| Year | 2023 |
| Volume | 317 |
| Pages | 116777 |
| Publication date | 2023-12-01 |
| Peer Reviewed | Yes |
| Open Access | Yes |
| Type | ARTICLE |
| Venue | Journal of Ethnopharmacology (JOURNAL) |
| Journal identifiers | ISSN: 0378-8741 • E-ISSN: 1872-7573 |
| Publisher | Elsevier BV (PUBLISHER) |
| DOI | 10.1016/j.jep.2023.116777 |
| PMID | 37311502 |
| OpenAlex | W4380266866 |
| Language | EN |
| Citations received | 3 |
| References cited | 22 |
SZF inhibits UA-induced renal tubular epithelial cell pyroptosis via by targeting NLRP3 to inhibit tubular inflammatory and prevent the progression of HUA-induced renal injury effectively
Hyperuricemia · Inflammasome · Inflammation · Pyroptosis · Traditional medicine · Uric acid · Chemistry · Gout, Hyperuricemia, Uric Acid · Inflammasome and immune disorders · Medicine · Spondyloarthritis Studies and Treatments · Internal Medicine · Pharmacology
Shizhifang alleviates hyperuricemia -induced renal injury by inhibiting Drp1 and maintaining mitochondrial homeostasis in renal tubular epithelial cells
The Terminalia chebula Retz extract treats hyperuricemic nephropathy by inhibiting TLR4/MyD88/NF-κB axis
Hippocampal PDHA1 gene knockout inhibits the Warburg effect leading to cognitive dysfunction and attenuates the beneficial effects of ZiBuPiYin recipe on cognition
| Unique citing works | 3 |
|---|---|
| Citations per year | 1,5 |
| Citation span | 2024 - 2025 (2) |
| Citation velocity | recent |
| Highly cited | No |
| Citation types | Neutral: 3 |